Pfizer predicts Covid-19 vaccines will remain 'multi-billion-dollar revenue generators'

Company plans to quadruple the price of the vaccine in the US once the US government stops buying doses and shifts to a private market
Pfizer predicts Covid-19 vaccines will remain 'multi-billion-dollar revenue generators'

Third-quarter sales of the Covid-19 vaccine came in at $4.4bn, blowing past estimates of $2.6bn.

Pfizer has raised its forecast for annual sales of its Covid-19 vaccine by $2bn to $34bn on demand for Omicron-targeted boosters, helping allay some investor worries over growth for the vaccinations.

The US drugmaker's shares rose over 2.5% at one stage in the session as its third-quarter profit beat estimates, mainly due to better-than-expected sales of the vaccine.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €120 €60

Best value

Monthly €10€5 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited